Forte Biosciences, INC Schedule 13G passive stakes

OrbiMed Advisors LLC, OrbiMed Capital GP IX LLC, and OrbiMed Capital LLC have filed an amendment to their Schedule 13G, reporting beneficial ownership of Forte Biosciences, Inc. common stock.

Affinity Asset Advisors, LLC and Michael Cho have reported beneficial ownership of 1,145,391 shares, representing 5.6% of Forte Biosciences, Inc. common stock as of June 30, 2026.

Janus Henderson Group Ltd. has updated its beneficial ownership filing for Forte Biosciences, Inc., reporting a 9.3% stake as of June 30, 2026.

Adage Capital Management, L.P. and associated individuals have reported beneficial ownership of 700,000 shares, representing 3.42% of Forte Biosciences, Inc. common stock.

Glazer Capital, LLC and Paul J. Glazer have filed a Schedule 13G, reporting beneficial ownership of Forte Biosciences, Inc. common stock has fallen below the 5% threshold.

Janus Henderson Group Ltd. has updated its beneficial ownership filing for Forte Biosciences, Inc., reporting a 2.5% stake.

Millennium Management LLC, along with affiliated entities and Israel A. Englander, has reported beneficial ownership of 3.2% of Forte Biosciences, Inc. common stock as of June 30, 2026.

Federated Hermes, Inc. and related entities have filed a Schedule 13G, reporting beneficial ownership of 10.31% of Forte Biosciences, Inc. common stock as of June 30, 2026.

Millennium Management LLC and Israel A. Englander have reported a 5.2% beneficial ownership stake in Forte Biosciences, Inc. via a Schedule 13G filing.

OrbiMed Advisors LLC and OrbiMed Capital LLC have filed an amendment to their Schedule 13G, reporting a combined 5.8% beneficial ownership in Forte Biosciences, Inc.

Alger Associates, Inc. has filed an amended Schedule 13G reporting a 10.2% beneficial ownership stake in Forte Biosciences, Inc.

Janus Henderson Group plc has filed a Schedule 13G, reporting beneficial ownership of 9.99% of Forte Biosciences, Inc. common stock.

Affinity Asset Advisors, LLC and Michael Cho have reported beneficial ownership of 1,011,890 shares, representing 7.3% of Forte Biosciences, Inc. common stock as of March 31, 2026.

Adage Capital Management, L.P., along with individuals Robert Atchinson and Phillip Gross, has reported beneficial ownership of 6.84% of Forte Biosciences, Inc. common stock as of March 31, 2026.

Affinity Asset Advisors and Michael Cho report a reduced beneficial ownership stake in Forte Biosciences, Inc. to 6.7%.

Point72 Asset Management, along with Point72 Capital Advisors Inc. and Steven A. Cohen, has disclosed a 6.3% beneficial ownership stake in Forte Biosciences, Inc.

Nemean Asset Management, LLC and Steven Michael Oliveira have disclosed a 2.4% beneficial ownership stake in Forte Biosciences, Inc. common stock.

Affinity Asset Advisors and Affinity Healthcare Fund have reported a combined 6.9% passive ownership stake in Forte Biosciences, Inc., totaling 862,400 shares.

Biotechnology Value Fund and its affiliates reported beneficial ownership of 0.5% of Forte Biosciences, Inc. common stock as of September 30, 2025.

Alger Associates, Inc. has filed an Amendment No. 7 to Schedule 13G, reporting beneficial ownership of 13.1% of Forte Biosciences, Inc.'s common stock.

Federated Hermes, Inc., along with its affiliates and the Donahue family, disclosed a 13.15% beneficial ownership stake in Forte Biosciences, Inc. common stock.

Federated Hermes, Inc. and related entities have filed an amended Schedule 13G, disclosing beneficial ownership of 1,478,647 shares, representing 11.89% of Forte Biosciences, Inc.'s common stock.

Alger Associates, Inc. has reported a 13.3% beneficial ownership stake in Forte Biosciences, Inc.'s common stock as of June 30, 2025.

Ikarian Capital and Neil Shahrestani have reported a 4.99% beneficial ownership stake in Forte Biosciences, Inc., including shares from warrants.

Janus Henderson Group plc and its affiliate have increased their beneficial ownership in Forte Biosciences, Inc. to 9.9% of common stock.

Boothbay Fund Management and Ari Glass disclose a reduced passive stake of 0.8% in Forte Biosciences, Inc. common stock.

Tybourne Capital Management and related entities have disclosed a 9.99% beneficial ownership stake in Forte Biosciences, Inc., including common stock and pre-funded warrants.

Federated Hermes, Inc. and affiliated entities have disclosed a passive beneficial ownership of 8.78% in Forte Biosciences, Inc. common stock as of June 30, 2025.

Alger Associates, Inc. has filed an Amendment No. 5 to Schedule 13G, disclosing a 14.2% beneficial ownership stake in Forte Biosciences, Inc. as of March 31, 2025.

Janus Henderson Group PLC and its affiliate, Janus Henderson Biotech Innovation Master Fund Ltd, have disclosed a 9.9% beneficial ownership stake in Forte Biosciences, Inc., as detailed in an amended Schedule 13G filing.